NUVB vs RXRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

NUVB

39.9
AI Score
VS
RXRX Wins

RXRX

44.1
AI Score

Investment Advisor Scores

NUVB

40score
Recommendation
SELL

RXRX

44score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric NUVB RXRX Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 555.6% -60.1% NUVB
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 39.9/100 44.1/100 RXRX
Profit Margin -88.2% 0.0% RXRX
Beta 1.00 1.00 Tie
AI Recommendation SELL HOLD RXRX

Relative Price Performance (Last 90 Days)

NUVB 1M: -5.5% · 3M: +27.5% RXRX 1M: -2.7% · 3M: +1.6%

Current Technical Phase

NUVB

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 40

RSI (14): 39.8 · Price: $6.07

RXRX

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope 0.1%) with fading momentum, RSI 46

RSI (14): 45.6 · Price: $3.20

Fundamentals Snapshot

Metric NUVB RXRX
Market Cap
Forward P/E -404.7 -3.6
Trailing P/E
Revenue (TTM)
Revenue Growth 5.6% -0.6%
Gross Margin 0.9% -7.2%
Operating Margin -1.6% -17.6%
EPS -0.42 -0.98
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, RXRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.